gvtcx

NP47825 Multiple Sclerosis Medicines

The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Value£51,517,832
Statuscomplete
Category (CPV) 33600000
RegionScotland
Deadline7 Feb 2025
Procedureopen
OCIDocds-h6vhtk-04ce06

Awards (8)

This procurement was awarded to 8 suppliers. Values shown are per-award; the notice total is £51,517,832.

SupplierValueDateStatus
Biogen Idec Ltd shared · · active
Merck Serono Limited shared · · active
Orifarm UK shared · · active
Ranbaxy (UK) Ltd shared · · active
Sandoz Ltd shared · · active
STADA UK - Thornton & Ross shared · · active
Teva UK Ltd shared · · active
Viatris UK Healthcare Ltd shared · · active

description

Supply of multiple sclerosis medicines to NHS Scotland.

notice history

3 notices published against this procurement.

PublishedTypeRegimeNotice
7 Jan 2025 Contract notice (F02) Earlier regulations 000410-2025
8 Jan 2025 Corrigendum (F14) Earlier regulations 000437-2025
2 May 2025 Contract award notice (F03) Earlier regulations 018635-2025

more from The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Find a Tender. Contact details for named individuals are not reproduced on this site.